Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for securities fraud, alleging that the company made misleading statements regarding its infant formula business and failed to disclose significant operational issues [1][11]. Summary by Sections Lawsuit Details - The lawsuit was filed in the U.S. District Court for the Southern District of New York on behalf of shareholders who acquired Perrigo securities between February 27, 2023, and November 4, 2025 [1]. - Plaintiffs are pursuing claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1]. Financial Performance and Issues - In November 2022, Perrigo acquired Nestlé's Gateway infant formula plant and the rights to the Good Start brand for $170 million [3]. - On February 27, 2024, Perrigo reported a 50% decline in earnings per share compared to the previous year, attributing this to remediation costs in the infant formula business, which were estimated to be an additional $35 million to $45 million [4]. - Following this announcement, Perrigo's share price fell by $4.87, or 15.14%, closing at $27.30 [5]. - On May 7, 2024, the company reported a 34.5% decrease in net sales for the first quarter, with gross margin declining by 90 basis points [6]. - The share price dropped by $3.28, or 9.8%, to close at $30.15 on the same day [7]. - On August 6, 2025, Perrigo disclosed that production issues led to scrapping approximately $11 million of inventory, resulting in a share price decline of $3.01, or 11.31%, to close at $23.61 [8]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business and slashed its fiscal year 2025 outlook, cutting net sales growth guidance to -2.5% to -3% from a previous expectation of 0% to 3% [9]. - The stock price fell by $5.09, or 25.2%, to close at $15.10 on the same day [10]. Allegations in the Lawsuit - The lawsuit alleges that Perrigo's management made materially false and misleading statements and failed to disclose adverse facts about the infant formula business, including: 1. Significant underinvestment in maintenance and operational improvements [11]. 2. The need for substantial capital expenditures beyond stated estimates for remediation [11]. 3. Manufacturing deficiencies in the infant formula facility [11]. 4. Overstated financial results, including earnings and cash flow [11]. 5. Misleading positive statements regarding the company's business and prospects [11].

Core Insights - Perrigo Company plc (NYSE:PRGO) is recognized as one of the 15 Best 52-Week Low Dividend Stocks to Invest in [1] - Canaccord has maintained a Buy rating on Perrigo while reducing its price target from $40 to $20, citing weaker-than-expected sales despite Q3 results beating expectations [2] - The company reported Q3 2025 revenue of $1.04 billion, a decline of 4.06% year-over-year, with operating income decreasing to $73 million from $80 million [3] Financial Performance - Q3 2025 revenue was $1.04 billion, down 4.06% compared to the same quarter last year [3] - Operating income for Q3 2025 was $73 million, a decrease from $80 million in the previous year [3] - The company experienced soft over-the-counter (OTC) consumption but gained market share in five of seven store-brand categories [3] Strategic Developments - Perrigo announced a strategic review of its infant formula business, focusing on higher-margin branded products due to challenges with quality issues and contamination risks in manufacturing [4] - The company is a leading supplier of store-brand baby formula, which is sold at lower prices compared to branded options [4] Company Overview - Perrigo is a leading consumer health company with over a century of experience in delivering high-quality health and wellness solutions, primarily in North America and Europe [5]

Core Insights - Holzer & Holzer, LLC is investigating Perrigo Company plc for potential compliance issues with federal securities laws following a disappointing earnings report and lowered full-year guidance [1] - Perrigo's third-quarter earnings revealed a 4.4% decline in organic net sales, attributed to a 1.6% decrease from the global OTC business and a 2.8% decline from businesses under review, specifically Oral Care and Infant Formula [1] Financial Performance - For the third quarter ended September 27, 2025, Perrigo reported a 4.4% decline in organic net sales [1] - The decline in organic net sales was impacted by a 1.6% decrease from the global OTC business due to soft category consumption [1] - Additionally, a 2.8% decline was noted from businesses under review, particularly in Oral Care and Infant Formula [1] Stock Market Reaction - Following the earnings announcement and guidance revision, Perrigo's stock price experienced a drop [1]

Core Viewpoint - Glancy Prongay & Murray LLP has initiated an investigation into Perrigo Company plc regarding potential violations of federal securities laws affecting investors [1] Summary by Relevant Sections - **Investigation Announcement** - The law firm is representing investors who may have incurred losses related to Perrigo Company plc [1] - **Investor Call to Action** - Investors who lost money on Perrigo Company plc are encouraged to inquire about pursuing claims to recover their losses [1]

Did You Suffer Losses in Perrigo Company plc (PRGO)? Contact Levi & Korsinsky About Securities Fraud ClaimsNovember 13, 2025 3:32 PM EST | Source: Levi & Korsinsky, LLPNew York, New York--(Newsfile Corp. - November 13, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Perrigo Company plc ("Perrigo Company plc") (NYSE: PRGO) concerning possible violations of federal securities laws.Perrigo issued a press release on November 5, 2025, "announc[ing] that it is i ...

Core Viewpoint - An investigation has been announced regarding Perrigo Company plc for potential violations of federal securities laws, which may impact investors who have suffered losses [1] Company Summary - Perrigo Company plc is under scrutiny for possible legal violations that could affect its investors [1] - The Law Offices of Howard G. Smith are reaching out to investors who may have incurred losses to discuss potential claims for recovery [1]

Core Viewpoint - Perrigo Company plc is under investigation for potential violations of federal securities laws, which may impact investors who have incurred losses [1] Investigation Details - The investigation is initiated by the Law Offices of Frank R. Cruz on behalf of investors [1] - The focus is on the company's financial disclosures and compliance with securities regulations [1] Investor Impact - Investors who lost money on Perrigo Company plc are encouraged to inquire about pursuing claims to recover their losses [1] - The investigation follows the release of Perrigo's third quarter financial results for 2025, indicating potential concerns regarding the company's financial health [1]

Core Insights - Perrigo Company plc is under investigation for possible violations of federal securities laws, as announced by Levi & Korsinsky [1] - On November 5, 2025, Perrigo announced a strategic review of its infant formula business, which includes reassessing a previously announced investment of $240 million [2] - Following the announcement of the strategic review, Perrigo's stock price dropped over 25% on the same day [2] Company Developments - The strategic review aims to accelerate cash flows and optimize the impact of the portfolio [2] - The review will consider a range of alternatives for the infant formula business [2] Legal Context - Levi & Korsinsky LLP has a history of representing investors in securities litigation and has secured significant settlements for shareholders [3] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [3]

Core Viewpoint - Perrigo Company plc (NYSE:PRGO) has experienced significant stock decline, reaching a new 52-week low due to weak net sales and a strategic review of its infant formula business [1][3]. Financial Performance - Perrigo's stock fell to $15.05 during intra-day trading, ultimately closing at $15.10, reflecting a 25.21% decrease [2]. - The company's net sales decreased by 4% to $1.043 billion from $1.087 billion year-over-year, impacted by lower organic sales and divestitures [2]. - Despite the sales decline, Perrigo reported a net income of $7.5 million, a recovery from a $21 million net loss in the same period last year [3]. Strategic Review - Perrigo is conducting a strategic review of its infant formula business, which may lead to a potential sale [3]. - The review aims to ensure the company's portfolio is positioned for sustainable growth and free cash flow generation, as stated by the President and CEO Patrick Lockwood-Taylor [4]. - The company acknowledges that while its infant formula operations have stabilized, the changing external environment has made it less strategic in alignment with its consumer health OTC businesses [5].

Core Insights - Perrigo (PRGO) reported adjusted earnings of 80 cents per share in Q3 2025, exceeding the Zacks Consensus Estimate of 75 cents, but down 1.2% year over year due to lower sales volume [1][9] - Net sales decreased by 4.1% year over year to $1.04 billion, missing the Zacks Consensus Estimate of $1.10 billion, primarily due to weak performance in the infant formula and oral care segments [2][9] - The company has lowered its 2025 sales guidance, now expecting a decline of 2.5-3%, a shift from previous guidance of 0-3% growth, which contributed to a 12% drop in stock price during pre-market trading [7][9] Financial Performance - Sales in the Consumer Self Care Americas (CSCA) segment were $646 million, down 3.8% year over year, missing estimates of $664 million [5] - The Consumer Self Care International (CSCI) segment reported net sales of $398 million, down 4.5% year over year, also missing estimates of $432 million [6] - Organic net sales declined 4.4%, with a 5.7% drop at constant currency rates, indicating ongoing challenges in the market [3][9] Strategic Initiatives - Perrigo is initiating a strategic review of its infant formula business, which is projected to generate $360 million in net sales for 2025, representing less than 10% of total annual net sales [12] - The review is part of the company's "Three-S" plan (Stabilize, Streamline, Strengthen) aimed at maximizing shareholder value, with no specific timeline set for completion [12] Guidance Adjustments - The company has revised its adjusted EPS guidance for 2025 to a range of $2.70-$2.80, down from $2.90-$3.10, and adjusted gross margin expectations to 39% from 40% [11] - The adjusted operating margin guidance remains near 15% [11]